10-Q: enVVeno Medical Faces FDA Setback, Nasdaq Delisting Threat

enVVeno Medical received a not-approvable letter from the FDA for its VenoValve PMA, leading to an appeal, while also facing a Nasdaq minimum bid price deficiency.

Summary

• Reported a net loss of $4.5 million for the three months ended September 30, 2025, an improvement from $5.6 million in the same period of 2024.
• The year-to-date net loss for the nine months ended September 30, 2025, was $15.7 million, a slight increase from $15.6 million for the same period in 2024.
• Cash and investments decreased from $43.2 million at December 31, 2024, to $31.0 million as of September 30, 2025.
• Received a 'not-approvable letter' from the FDA on August 19, 2025, for the VenoValve Pre-Market Approval (PMA) application, citing insufficient benefit-risk profile, concerns about bias, and safety issues related to the surgical procedure.
• Filed a supervisory appeal with the FDA on September 18, 2025, and held an in-person meeting in October 2025, with a decision expected by the end of 2025.
• Received a Nasdaq deficiency notice on October 7, 2025, for failing to meet the minimum $1.00 bid price requirement, with 180 days to regain compliance.
• The VenoValve U.S. pivotal study is in post-enrollment follow-up, with positive one-year and interim two-year efficacy data reported, including significant rVCSS improvement, pain reduction, and ulcer healing.
• Development of the enVVe non-surgical valve is progressing, with pre-clinical GLP study completed, but its IDE application is delayed pending VenoValve regulatory clarity.

Sentiment

Score: 3

Explanation: The FDA's 'not-approvable' letter for the lead product and the Nasdaq delisting warning are major negative developments. While clinical data for VenoValve is positive, the regulatory hurdle is substantial. The company's cash position is declining, and a future capital raise is anticipated, adding financial uncertainty.

Positives

• Net loss for the three months ended September 30, 2025, decreased to $4.5 million from $5.6 million in Q3 2024, representing a 20% improvement.
• Research and development expenses decreased by $0.3 million (10%) in Q3 2025 and $0.7 million (8%) year-to-date, primarily due to lower VenoValve pivotal study costs.
• Selling, general and administrative expenses decreased by $1.0 million (31%) in Q3 2025, driven by lower non-recurring legal costs and a partial recovery of uncollectible prepaid clinical costs.
• VenoValve pivotal study showed strong efficacy: 85% of patients experienced a clinically meaningful benefit (defined as a three or more point improvement in revised Venous Clinical Severity Score, rVCSS) at one year, with an average rVCSS improvement of 7.91 points.
• Patients in the VenoValve study experienced a 75% median reduction in pain and improvements in quality-of-life indicators at one year.
• For C6 patients with venous ulcers, ulcer area was reduced a median average of 87% at one year.
• Interim two-year follow-up data for VenoValve showed 83.3% of patients maintained a clinically meaningful benefit, with an average rVCSS improvement of 9.1 points.
• Two-year data also showed a 74% median reduction in leg pain and 60% of ulcers healed completely among C6 patients.
• High valve patency rates reported for VenoValve: 91% at 30 days, 97% at one year, and 100% at two years (n=30).
• The enVVe non-surgical transcatheter valve successfully completed its final wave of implants for the six-month pre-clinical GLP study.
• Management believes current capital resources of $31.0 million cash and investments are sufficient to meet obligations and sustain operations for at least one year.

Negatives

• Received a 'not-approvable letter' from the FDA for the VenoValve PMA application on August 19, 2025, citing insufficient benefit-risk profile, concerns about bias, and safety issues related to the open surgical procedure.
• Net loss for the nine months ended September 30, 2025, increased slightly to $15.7 million from $15.6 million in the prior year.
• Cash and investments decreased significantly from $43.2 million at December 31, 2024, to $31.0 million at September 30, 2025.
• Net cash used in operating activities increased to $12.1 million for the nine months ended September 30, 2025, from $11.7 million in the prior year.
• Selling, general and administrative expenses increased by $0.5 million (6%) year-to-date, partly due to non-recurring severance and a reserve for uncollectible prepaid clinical costs.
• The company anticipates its cash burn rate will increase from approximately $4 million per quarter to between $5 million and $7 million per quarter.
• Safety concerns raised by the FDA were attributed to the VenoValve open surgical procedure, including 12 target vein thromboses, 10 surgical pocket hematomas, 4 other bleeds, and 7 deep wound infections at one year.
• The FDA specifically noted the lack of a specific hemodynamic measurement that correlates with patient improvement, raising concerns about bias in the VenoValve study data.

Risks

• Uncertainty regarding FDA approval for the VenoValve PMA application following the 'not-approvable letter' and ongoing supervisory appeal.
• Risk of not regaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share by April 6, 2026, potentially leading to delisting.
• The need to raise additional capital in the future to sustain operations, pursue product development, and penetrate markets, with no assurance of successful financing.
• Future capital requirements are dependent on the success of clinical trials and product development, and the ability to bring products to market.
• The VenoValve and enVVe may not receive FDA approval, and there is no assurance that the alternative effectiveness pathway proposed to the FDA will be accepted.
• The company expects to continue incurring losses for the foreseeable future.
• Inherent limitations in disclosure controls and procedures or internal control over financial reporting mean they may not prevent or detect all errors and fraud.

Future Outlook

The company expects to continue incurring losses for the foreseeable future and anticipates its cash burn rate to increase from approximately $4 million per quarter to between $5 million and $7 million per quarter as it conducts clinical studies and works towards commercialization. FDA approval for VenoValve is uncertain, with a decision on the supervisory appeal expected by the end of 2025. The IDE application for enVVe is expected to be filed in Q1 2026, pending clarity from the FDA on VenoValve regulatory issues. The company will need to raise additional capital in the future to sustain operations and pursue product development.

Management Comments

• Management believes that the Company's capital resources are sufficient to meet its obligations as they become due within one year after the date of this Quarterly Report, and sustain operations.
• We expect the VenoValve to be eligible for FDA approval first, followed approximately three years later by enVVe.
• If approved, we expect the VenoValve and enVVe to co-exist, with the VenoValve as a surgical replacement venous valve option and enVVe as a non-surgical replacement venous valve option.
• The Company is confident that explaining this data to supervisory management in a focused appeal setting may lead to a positive outcome, with a decision expected by the end of 2025.
• Because there are no established industry or regulatory standards to determine the effectiveness for a replacement venous valve, it is necessary for the Company and the Agency to establish a new regulatory pathway for VenoValve effectiveness.
• The Company worked collaboratively with the FDA over the past several years to help ensure that the Company was collecting the necessary data to support effectiveness of the VenoValve and that dialogue with respect to effectiveness is continuing as part of this appeal.
• At the meeting, the Company proposed an alternative effectiveness pathway for the VenoValve, supported by data already collected in SAVVE.
• The Company expects to hear from the FDA about this stage of the appeal process by the end of 2025.
• The Company is waiting until certain regulatory issues with respect to the VenoValve are resolved with the FDA before filing the IDE for enVVe, which the Company expects to file in the first quarter of 2026.
• We anticipate that our cash burn rate will increase from current levels of approximately $4 million per quarter to between $5 million and $7 million per quarter as we conduct our clinical studies and work toward bringing our product candidates to market.
• We have historically funded our operations through financing activities... and will need to raise additional capital in the future.

Industry Context

Chronic Venous Disease (CVD) is the world's most prevalent chronic disease, impacting approximately 70% of the adult U.S. population, with severe Chronic Venous Insufficiency (CVI) affecting 2.5 million to 3.5 million patients. There are currently no FDA-approved devices for surgical or non-surgical replacement venous valves, and no effective treatments for deep venous CVI caused by incompetent valves. This positions enVVeno Medical's VenoValve and enVVe as potential first-in-class solutions addressing a significant unmet medical need and a market estimated to exceed $20 billion annually in direct medical costs for venous ulcer sufferers.

Comparison to Industry Standards

• There are currently no FDA-approved devices as surgical or non-surgical replacement venous valves, making enVVeno Medical's VenoValve and enVVe potential first-in-class solutions.
• The company's VenoValve has been granted Breakthrough Device designation by the FDA, indicating its potential to provide more effective treatment for a life-threatening or irreversibly debilitating disease or condition.
• The VenoValve's clinical data, showing 85% of patients experiencing a clinically meaningful benefit (>=3 point rVCSS improvement) at one year and 83.3% maintaining it at two years, along with significant pain reduction and ulcer healing, suggests strong clinical performance in an area with no current effective device treatments.
• The FDA's 'not-approvable letter' highlights the challenge of establishing regulatory pathways for novel devices without existing industry or regulatory standards for effectiveness, particularly regarding the need for specific hemodynamic measurements correlating with patient improvement.

Stakeholder Impact

• Shareholders: Potential for significant share price volatility due to FDA setback and Nasdaq delisting threat. Dilution risk from future capital raises.
• Patients with CVI: Delay in potential access to VenoValve, a novel treatment for a debilitating condition with no current effective device treatments.
• Employees: Uncertainty regarding the company's future and product timelines due to regulatory challenges.
• Creditors/Investors: Increased financial risk due to ongoing losses, declining cash, and the need for future capital.

Next Steps

• Await decision from the FDA on the VenoValve supervisory appeal by the end of 2025.
• Regain compliance with Nasdaq's minimum bid price requirement by April 6, 2026, potentially through a reverse stock split if necessary.
• File the IDE application for enVVe in Q1 2026, after VenoValve regulatory issues are resolved.
• Continue to fund operations and product development, likely requiring additional capital raises.
• Continue post-enrollment follow-up for the VenoValve U.S. pivotal study.

Key Dates

Recommendation

The FDA's 'not-approvable' letter for the VenoValve PMA is a critical setback for the company's lead product, introducing significant regulatory uncertainty and delaying commercialization. This, coupled with the Nasdaq minimum bid price deficiency and the explicit need for future capital raises amidst increasing cash burn, points to substantial near-term risks. While clinical data for VenoValve shows promise, the regulatory hurdle is now much higher, and the path to market is unclear. The financial position is deteriorating, and the stock faces potential delisting. A seasoned investor would likely view these combined factors as a strong signal to exit the position due to heightened risk and uncertainty.

Keywords

enVVeno Medical, NVNO, SEC Filing, 10-Q, Medical Device, Deep Venous Disease, Chronic Venous Insufficiency, CVI, VenoValve, enVVe, FDA Approval, PMA, Clinical Trials, Nasdaq Listing, Bioprosthetic, Venous Valve, Financial Results, Q3 2025, Cash Burn, Regulatory Appeal